摘要
目的 探讨拉米夫定停药后复发率、临床特点、机制及防治。方法 对 4 1例经拉米夫定治疗慢性乙型肝炎患者停药后分别在 1、3、6月时观察血清ALT、HBeAg、抗HBe、HBVDNA变化情况。在拉米夫定治疗前、后出现HBeAg至抗HBe转换者为Ⅰ组 ;未出现者为Ⅱ组 ,对比两组患者停药 1、3、6月后ALT、HBV标志物的变化情况。结果 停药 1、3、6月时 ,Ⅰ、Ⅱ组ALT异常率分别为 11.1%和 15 .6 % (P >0 .0 5 )、11.1%和 34.3% (P >0 .0 5 )、2 2 .2 %和 6 2 .5 % (P <0 .0 5 ) ;HBVDNA转阳率为 11.1%和2 5 .0 % (P >0 .0 5 )、11.1%和 4 0 .6 % (P >0 .0 5 )、33.3%和 71.8% (P <0 .0 5 )。结论 对长期服用拉米夫定治疗的患者无论是否因发生血清转换而停药 ,都应继续监测肝功能 ,发生e抗原转换者 ,复发率低。
Objective To appraise the recueseme rate,clinical characteristics, mechanism after withdrawing lamivudine. Methods the level of ALT, HBeAg, HBV DNA of 41 patients after the treatment with lamiucdine were examined at 1,3,6months, These paients were divided into two groups(group I and II )according to whether HBeAg seroconvecation to anti-HBe or not. Results ALT abnormal rates of the two groups after,3,6 months were 11.1% and 15.6%(P>0.05),ll.l% and 34.3%(P>0.05);22.2% and 62.5%respectively,(P<0.05),HBV DNA recurrent positive rates of the two groups were 11.1% and 25.0%(P>0.05) 、11.1%and 40.6%(P>0.05),33.3%and 71.8%(P<0.05).Conclusion For those patients received long-term treatment of lamivudine, whether they had serum conversion of HBeAg/anti-HBe or not,they should be monitored liver function.
出处
《川北医学院学报》
CAS
2004年第2期30-31,共2页
Journal of North Sichuan Medical College
关键词
拉米夫定
慢性乙型肝炎
血清转氨酶
防治
lamivudne
chronic Hepatitis B
liver function serum conversion
